Treatment Information

Back

Prostate Cancer treatment details. Immunotherapy.

Kurume University School of Medicine, Kurume, Japan.

Survival: monthsCountry:Japan
Toxiciy Grade:2City/State/Province:Kurume
Treatments:ImmunotherapyHospital:Kurume University School of Medicine
Drugs:Journal:Link
Date:Jan 2004

Description:

Patients: This Phase I trial involved 10 patients with metastatic hormone refractory prostate cancer. All patients were also positive for human leukocyte antigen (HLA)-A2.

Treatment: The treatment consisted of immunotherapy – a peptide vaccination.

Toxicity: All ten patients developed grade 1 or 2 local redness and swelling at the injection site.

Results: There were no objective responses of measurable disease, but median survival was 22 months.

Correspondence: M. Noguchi, MD




Back